Keywords: cellegy, loss, deepens, expenses, increase, biotechnology, company
Cellegy loss deepens as expenses increase
Article | 13 May 2002
US biotechnology company Cellegy Pharmaceuticals has reportedfirst-quarter 2002 revenues of $267,000, a more than six-fold increase on the same period of 2001. Revenues ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
